このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

THE EVALUATION OF THE SAFETY AND PERFORMANCE OF AN INJECTABLE HYALURONIC ACID FILLER

2026年8月9日 更新者:Hallura Ltd.

PROSPECTIVE, INTERVENTIONAL, NON-RANDOMIZED, OPEN LABEL, BLINDED STUDY FOR THE EVALUATION OF THE SAFETY AND PERFORMANCE OF AN INJECTABLE HYALURONIC ACID FILLER

Evaluation of the safety and performance of the investigational device in its three concentrations for cheek and lips augmentation and correction of the nasolabial folds, assuming that the performance of the product will be demonstrated based on the responder rates observed compared to baseline.

調査の概要

研究の種類

介入

入学 (推定)

98

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

      • Tel Aviv、イスラエル
        • 募集
        • Ichilov Medical Center
        • コンタクト:
      • Tel Aviv、イスラエル、2069202
        • 完了
        • Hallura Ltd

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

はい

説明

Inclusion Criteria:

  1. Healthy Subject;
  2. Male or female, over the age of 18;
  3. Female patients of childbearing potential must declare in the ICF to be non-pregnant at visit 1a prior to initial injection and should use a contraceptive regimen recognized as effective since at least 12 weeks before the beginning of the study, and during the entire duration of the study.
  4. Subject seeking an aesthetic procedure on the face who can be classified into one of the following groups:

    1. Group1: Lip volume deficit with ROSSI score between 1.5 and 3 on at least the upper lip, or on both the upper and the lower lips with up to 1-point difference in ROSSI score between upper and lower lips;
    2. Group 2: Moderate to severe nasolabial folds (NLFs) with WSRS scale score 3 or 4 for each side of the face;
    3. Group 3: Mild to significant volume deficit at the cheeks level with MFVDS score 3 to 4 at each side, with up to 1-point difference in MFVDS scale score between the two sides.

    Blinded Live-Evaluator (BLE) and Injector (ILE) must independently agree that the criteria is met on the area to be treated, however concordance of the scores is not required.

  5. Subject willing to abstain from any aesthetic treatment on the treated area other than the treatments planned in the protocol during the study period.
  6. Subject informed and having signed and dated the EC approved informed consent form (ICF).
  7. Subjects agree that his/her imaging will be published without partial covering of the photo, meaning without Anonymization for R&D, business development, Marketing of Hallura and Publications and for evaluating the 3D imaging by cherry imaging for internal R&D use.

Exclusion Criteria:

In terms of population

  1. Subject with abnormal vision assessment at Baseline: either Snellen acuity test worse than 20/40 (with corrections, if applicable) or abnormal confrontational visual field test or abnormal ocular motility test.
  2. Subject who is pregnant or nursing or planning to become pregnant during the study.
  3. Subject with a tattoo, a scar, moles, too many hairs or anything on the studied zones which might interfere with the evaluation.
  4. Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship, such as social or sanitary establishment.
  5. Subject suspected to be non-compliant according to the investigator's judgment.
  6. Participation in another clinical trial concurrent with this study.

    In terms of associated pathology and concomitant treatment

  7. Subject with a condition or receiving a medication which, in the investigator's judgment, puts the subject under risk.
  8. Subject suffering from a severe or progressive disease or any other pathology that may interfere with the evaluation of the study results.
  9. Subject with mid-face volume deficit due to congenital defect, trauma, abnormalities in adipose tissue related to immune-mediated diseases such as generalized lipodystrophy (e.g., juvenile dermatomyositis), partial lipodystrophy (e.g., Barraquer-Simons syndrome), inherited disease, or HIV-related disease, and/or severe malocclusion or dentofacial or maxillofacial deformities.
  10. Subject with known history of or suffering from autoimmune disease and/or immune deficiency.
  11. Subject suffering from inflammatory and/or infectious cutaneous disorders in or near the studied zones (herpes, acne, mycosis, papilloma, rosacea, blotches or other pathology on the studied zones, at the investigator appreciation). Subject with recurrent herpes is not eligible even if asymptomatic at time of inclusion.
  12. Subject who has a known history of multiple allergies, allergic/anaphylactic reactions including allergy to lidocaine or anaesthetics of the amide type, to hyaluronic acid products, or to Gram-positive bacterial proteins.
  13. Subject with a past history of streptococcal disease, such as acute rheumatic fever or recurrent sore throats.
  14. Subject with a history of precancerous lesions/skin malignancies.
  15. Subject predisposed to keloids or hypertrophic scarring.
  16. Subject with known history of hyper- or hypo-pigmentation in face.
  17. Subject prone to develop inflammatory skin conditions or having tendency to bleeding disorders.
  18. Subject having received high dose of Lidocaine (more than 200mg) and/or high dose of anaesthetics structurally related to amide-type during the week before the injection session.
  19. Have received (or is planning to receive) anti-coagulation, anti-platelet, or thrombolytic medications (e.g., warfarin), anti-inflammatory drugs (oral/injectable corticosteroids or NSAIDs, e.g., aspirin, ibuprofen), or other substances known to increase coagulation time (vitamins or herbal supplements, e.g., Vitamin E, garlic, gingko), fish oil or vitamin C from 10 days pre- to 3 days post injection [Study device injections may be delayed as necessary to accommodate this 10-day washout period.]
  20. For group 1, abnormal rating in lip movement / lip function / lip sensation.
  21. Subject undergoing one of the following systemic or topical (on the test area) treatments:
  22. anti-histamines during the 2 weeks prior to study start;
  23. immunosuppressors and/or corticoids during the 4 weeks prior to study start;
  24. retinoids during the 6 months prior to study start.
  25. Subjects suffering from untreated epilepsy;

    In terms of lifestyle

  26. Subject having received injection with a temporary bioresorbable facial dermal filler (e.g., hyaluronic acid, collagen, autologous fat, etc.) within the past 12 months prior to study start.
  27. Botulinum toxin injections, mesotherapy, or resurfacing (laser, photomodulation, intense pulsed light, radio frequency, dermabrasion, chemical peel, or other ablative or non-ablative procedures) within 6 months prior to entry in the study.
  28. Subjects having received at any time permanent facial implants (e.g. polyacrylamide, PMMA, silicone) anywhere in the face or neck.
  29. Had undergone semi-permanent dermal filler treatment (e.g., calcium hydroxylapatite, poly-L-lactic acid, etc.) in the face within 24 months before enrolment.
  30. Subject having received at any time a treatment with tensor threads or gold strands on the face.
  31. Intensive exposure to sunlight or UV-rays within the previous month and/or foreseen during the study;
  32. Subject with an excessive consumption of alcohol (more than 2 glasses of wine per day) and/or tobacco (more than 10 cigarettes per day).

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Group 1 - Lips
HLR-1, maximum of 3ml per upper and lower lip area, (1.5ml max at the touch-up treat

Initial injection of HLR-1 and a touch-up treatment can occur 30 ± 7 days after the initial treatment if the Injector and Subject determine that additional HLR Dermal Filler would improve the aesthetic outcome.

The Maximum allowable dose for the touch up treatments is half of initial dose for the whole lips.

実験的:Group 2 - Nasolabial folds (NLF)
HLR-2, maximum of 3ml per NLF, (1.5ml max at the touch-up treatment, if performed) injected in the mid to deep dermis.

Initial injection of HLR-1 and a touch-up treatment can occur 30 ± 7 days after the initial treatment if the Injector and Subject determine that additional HLR Dermal Filler would improve the aesthetic outcome.

The Maximum allowable dose for the touch up treatments is half of initial dose by side.

実験的:Group 3 - Cheeks
HLR-3, maximum of 4ml per side, (2 ml max at the touch-up treatment, if performed) injected in the deep dermis or subcutaneous to supraperiosteal layers of the cheeks.

Initial injection of HLR-1 and a touch-up treatment can occur 30 ± 7 days after the initial treatment if the Injector and Subject determine that additional HLR Dermal Filler would improve the aesthetic outcome.

The Maximum allowable dose for the touch up treatments is half of initial dose by side.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Responder Rate
時間枠:3 months for Group 1, 6 months for Groups 2 and 3

Clinical scoring:

The assessment of lip volume, wrinkles severity of nasolabial folds and cheeks volume will be performed by the ILE and validated with BLE (blinded live evaluator) assessment using the respectively structured scale ROSSI, WSRS or MFVDS. At each scoring event, one score for the upper lip will be given for subjects in group 1, two scores for right and left NLF for subjects in group 2 and two scores for right and left cheeks for subjects in group 3.

For each group, in order to demonstrate a product efficacy, the responder rate proportion in clinical scoring should be significantly higher than 60% using a one-tailed binomial test at the Alpha=0.05 significance level.

3 months for Group 1, 6 months for Groups 2 and 3
Safety Evaluation
時間枠:12 months after the injection

Prior to statistical analyses, all the AEs will be coded using the Medical Dictionary MedDRA®.

Will be presented by System Organ Class and Preferred Term:

  • All Adverse Events
  • All Serious Adverse Events
  • All Adverse Device Effects

The number and percentage of patients experiencing at least one AE / SAE / ADE occurring over 6 months and 12 months after the injection will be provided as well.

AEs will also be tabulated by:

  • Seriousness criterion
  • Severity
  • Relationship with the product
  • Relationship with CIP procedure
  • Outcome

The individual listing of AE will be provided. The main analysis will be performed globally on the entire safety population over the 3 groups. Analysis per group will also be realized, as well as broken down by sub-group of subjects with and without touch-up.

12 months after the injection

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年1月9日

一次修了 (推定)

2027年1月1日

研究の完了 (推定)

2027年1月1日

試験登録日

最初に提出

2026年8月9日

QC基準を満たした最初の提出物

2026年8月9日

最初の投稿 (実際)

2026年8月13日

学習記録の更新

投稿された最後の更新 (実際)

2026年8月13日

QC基準を満たした最後の更新が送信されました

2026年8月9日

最終確認日

2026年8月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • HL01IL2022

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する